rabbit anti brain derived neurotrophic factor bdnf antibody Search Results


rabbit anti mouse bdnf  (Boster Bio)
93
Boster Bio rabbit anti mouse bdnf
Neurotrophic factor expression in surrounding injured brain tissues following human umbilical cord blood mesenchymal stem cell transplantation. (A–C) Nerve growth factor (NGF) protein expression (immunohistochemistry, × 200); (D–F) brain-derived neurotrophic factor <t>(BDNF)</t> protein expression (immunohistochemistry, × 200); (G–I) BDNF mRNA expression ( in situ hybridization, × 400). (A, D, G) Results (absorbance) are expressed as mean ± SD from six rats in each group at each time point. a P < 0.05, vs . model group ( t -test was used to specify differences between two groups at the corresponding time points); (B, E, H) model group at 14 days after transplantation; (C, F, I) transplantation group at 14 days after transplantation. Arrows: NGF protein-, BDNF protein-, and BDNF mRNA-positive cells.
Rabbit Anti Mouse Bdnf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti mouse bdnf/product/Boster Bio
Average 93 stars, based on 1 article reviews
rabbit anti mouse bdnf - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
py816 trkb fl  (Boster Bio)
93
Boster Bio py816 trkb fl
A – D Kinetics of TrkB-FL downregulation. Primary cortical cultures were treated with 100 μM NMDA and its co-agonist 10 μM glycine (hereafter referred to as ‘NMDA’). Immunofluorescence ( A ) and immunoblotting ( B ) used a C-terminal (C-ter) isoform-specific antibody (TrkB-FL Ct) recognizing both the full-length protein (FL) and the intracellular fragment (f32). A Shows TrkB-FL (green) and nuclei (blue, DAPI stain). Arrowheads indicate varicosities in neuronal projections. Scale bar: 20 μm. Insets show cell body details for untreated cells and cells treated with NMDA for 120 min. B Compares the decrease in TrkB-FL and formation of f32 with PSD-95 downregulation, detected using a C-terminal antibody (PSD-95 Ct). Calpain activation was confirmed by the accumulation of characteristic spectrin breakdown products (BDPs; 150 and 145 kDa). Neuron-specific enolase (NSE) served as a loading control for protein normalization. C , D Quantification of normalized TrkB-FL and PSD-95 levels, shown relative to levels in the absence of NMDA (control). Data are represented as means ± SD. Statistical analysis: one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test (** P < 0.01, *** P < 0.001, **** P < 0.0001; 0-90 min, n = 5; 120 min, n = 3). E , F Effect of dynasore preincubation (80 μM, 30 min) on TrkB-FL levels after 2 h NMDA treatment. Data are means ± SD ( n = 4); statistical analysis as above (* P < 0.05). G Sequences of the cell-penetrating neuroprotective peptide (MTFL 457 ) and control peptide (MTMyc). Both contain Tat amino acids (aa) 47–57 (italic), followed by rat TrkB-FL aa 457-471 (light blue) or c-Myc aa 408-421 (dark blue), respectively. H , I Effect of peptide preincubation (25 μM, 30 min) on TrkB-FL shedding and processing during NMDA treatment. Culture media were analyzed using an antibody against the TrkB-FL extracellular domain (panTrkB), which recognizes the ectodomains (ECDs) of all isoforms (TrkB-ECD), to assess receptor shedding by metalloproteinase (MP) activation. Total lysates were analyzed with the TrkB-FL Ct antibody to evaluate TrkB-FL calpain processing via f32 production. Relative TrkB-ECD levels are shown as means ± SD (0-4 h, n = 7; 6 h, n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test (** P < 0.01, **** P < 0.0001, comparing each peptide + NMDA vs. peptide alone; # P < 0.05, #### P < 0.0001, comparing MTMyc vs. MTFL 457 at each time point). J , K Effect of NMDA on total and cell-surface <t>pY816-TrkB-FL</t> levels. Cultures were preincubated with peptides as above, then treated briefly with NMDA (1 h) to minimize receptor degradation. Cell-surface proteins were biotin-labeled and precipitated, then compared to corresponding total lysates. Data are represented as means ± SD ( n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test ( n.s . = n ot significant; ** P < 0.01, comparing NMDA vs. no NMDA; ## P < 0.01, comparing MTMyc + NMDA vs. MTFL 457 + NMDA).
Py816 Trkb Fl, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/py816 trkb fl/product/Boster Bio
Average 93 stars, based on 1 article reviews
py816 trkb fl - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
gdnf antibodies  (Boster Bio)
90
Boster Bio gdnf antibodies
<t>A:</t> <t>BDNF</t> band at approximately 27 kDa. B: <t>GDNF</t> band at approximately 20 kDa.
Gdnf Antibodies, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gdnf antibodies/product/Boster Bio
Average 90 stars, based on 1 article reviews
gdnf antibodies - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Neurotrophic factor expression in surrounding injured brain tissues following human umbilical cord blood mesenchymal stem cell transplantation. (A–C) Nerve growth factor (NGF) protein expression (immunohistochemistry, × 200); (D–F) brain-derived neurotrophic factor (BDNF) protein expression (immunohistochemistry, × 200); (G–I) BDNF mRNA expression ( in situ hybridization, × 400). (A, D, G) Results (absorbance) are expressed as mean ± SD from six rats in each group at each time point. a P < 0.05, vs . model group ( t -test was used to specify differences between two groups at the corresponding time points); (B, E, H) model group at 14 days after transplantation; (C, F, I) transplantation group at 14 days after transplantation. Arrows: NGF protein-, BDNF protein-, and BDNF mRNA-positive cells.

Journal: Neural Regeneration Research

Article Title: Transplantation of human umbilical cord blood mesenchymal stem cells to treat a rat model of traumatic brain injury ★

doi: 10.3969/j.issn.1673-5374.2012.10.004

Figure Lengend Snippet: Neurotrophic factor expression in surrounding injured brain tissues following human umbilical cord blood mesenchymal stem cell transplantation. (A–C) Nerve growth factor (NGF) protein expression (immunohistochemistry, × 200); (D–F) brain-derived neurotrophic factor (BDNF) protein expression (immunohistochemistry, × 200); (G–I) BDNF mRNA expression ( in situ hybridization, × 400). (A, D, G) Results (absorbance) are expressed as mean ± SD from six rats in each group at each time point. a P < 0.05, vs . model group ( t -test was used to specify differences between two groups at the corresponding time points); (B, E, H) model group at 14 days after transplantation; (C, F, I) transplantation group at 14 days after transplantation. Arrows: NGF protein-, BDNF protein-, and BDNF mRNA-positive cells.

Article Snippet: Primary antibodies were incubated overnight at 4°C in wet box with the following dilutions: rat anti-human BrdU monoclonal antibody (1:150; Beijing Boaosen Biotechnology, China), rabbit anti-mouse BDNF (1:150; Boster, Wuhan, China), NGF (1:150; Boster), VEGF (1:150; Boster), CD34 (1:100; Boster), bFGF (1:100; Beijing Boaosen Biotechnology) polyclonal antibody.

Techniques: Expressing, Transplantation Assay, Immunohistochemistry, Derivative Assay, In Situ Hybridization

A – D Kinetics of TrkB-FL downregulation. Primary cortical cultures were treated with 100 μM NMDA and its co-agonist 10 μM glycine (hereafter referred to as ‘NMDA’). Immunofluorescence ( A ) and immunoblotting ( B ) used a C-terminal (C-ter) isoform-specific antibody (TrkB-FL Ct) recognizing both the full-length protein (FL) and the intracellular fragment (f32). A Shows TrkB-FL (green) and nuclei (blue, DAPI stain). Arrowheads indicate varicosities in neuronal projections. Scale bar: 20 μm. Insets show cell body details for untreated cells and cells treated with NMDA for 120 min. B Compares the decrease in TrkB-FL and formation of f32 with PSD-95 downregulation, detected using a C-terminal antibody (PSD-95 Ct). Calpain activation was confirmed by the accumulation of characteristic spectrin breakdown products (BDPs; 150 and 145 kDa). Neuron-specific enolase (NSE) served as a loading control for protein normalization. C , D Quantification of normalized TrkB-FL and PSD-95 levels, shown relative to levels in the absence of NMDA (control). Data are represented as means ± SD. Statistical analysis: one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test (** P < 0.01, *** P < 0.001, **** P < 0.0001; 0-90 min, n = 5; 120 min, n = 3). E , F Effect of dynasore preincubation (80 μM, 30 min) on TrkB-FL levels after 2 h NMDA treatment. Data are means ± SD ( n = 4); statistical analysis as above (* P < 0.05). G Sequences of the cell-penetrating neuroprotective peptide (MTFL 457 ) and control peptide (MTMyc). Both contain Tat amino acids (aa) 47–57 (italic), followed by rat TrkB-FL aa 457-471 (light blue) or c-Myc aa 408-421 (dark blue), respectively. H , I Effect of peptide preincubation (25 μM, 30 min) on TrkB-FL shedding and processing during NMDA treatment. Culture media were analyzed using an antibody against the TrkB-FL extracellular domain (panTrkB), which recognizes the ectodomains (ECDs) of all isoforms (TrkB-ECD), to assess receptor shedding by metalloproteinase (MP) activation. Total lysates were analyzed with the TrkB-FL Ct antibody to evaluate TrkB-FL calpain processing via f32 production. Relative TrkB-ECD levels are shown as means ± SD (0-4 h, n = 7; 6 h, n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test (** P < 0.01, **** P < 0.0001, comparing each peptide + NMDA vs. peptide alone; # P < 0.05, #### P < 0.0001, comparing MTMyc vs. MTFL 457 at each time point). J , K Effect of NMDA on total and cell-surface pY816-TrkB-FL levels. Cultures were preincubated with peptides as above, then treated briefly with NMDA (1 h) to minimize receptor degradation. Cell-surface proteins were biotin-labeled and precipitated, then compared to corresponding total lysates. Data are represented as means ± SD ( n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test ( n.s . = n ot significant; ** P < 0.01, comparing NMDA vs. no NMDA; ## P < 0.01, comparing MTMyc + NMDA vs. MTFL 457 + NMDA).

Journal: Cell Death & Disease

Article Title: Retrograde transport of neurotrophin receptor TrkB-FL induced by excitotoxicity regulates Golgi stability and is a target for stroke neuroprotection

doi: 10.1038/s41419-025-07990-6

Figure Lengend Snippet: A – D Kinetics of TrkB-FL downregulation. Primary cortical cultures were treated with 100 μM NMDA and its co-agonist 10 μM glycine (hereafter referred to as ‘NMDA’). Immunofluorescence ( A ) and immunoblotting ( B ) used a C-terminal (C-ter) isoform-specific antibody (TrkB-FL Ct) recognizing both the full-length protein (FL) and the intracellular fragment (f32). A Shows TrkB-FL (green) and nuclei (blue, DAPI stain). Arrowheads indicate varicosities in neuronal projections. Scale bar: 20 μm. Insets show cell body details for untreated cells and cells treated with NMDA for 120 min. B Compares the decrease in TrkB-FL and formation of f32 with PSD-95 downregulation, detected using a C-terminal antibody (PSD-95 Ct). Calpain activation was confirmed by the accumulation of characteristic spectrin breakdown products (BDPs; 150 and 145 kDa). Neuron-specific enolase (NSE) served as a loading control for protein normalization. C , D Quantification of normalized TrkB-FL and PSD-95 levels, shown relative to levels in the absence of NMDA (control). Data are represented as means ± SD. Statistical analysis: one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test (** P < 0.01, *** P < 0.001, **** P < 0.0001; 0-90 min, n = 5; 120 min, n = 3). E , F Effect of dynasore preincubation (80 μM, 30 min) on TrkB-FL levels after 2 h NMDA treatment. Data are means ± SD ( n = 4); statistical analysis as above (* P < 0.05). G Sequences of the cell-penetrating neuroprotective peptide (MTFL 457 ) and control peptide (MTMyc). Both contain Tat amino acids (aa) 47–57 (italic), followed by rat TrkB-FL aa 457-471 (light blue) or c-Myc aa 408-421 (dark blue), respectively. H , I Effect of peptide preincubation (25 μM, 30 min) on TrkB-FL shedding and processing during NMDA treatment. Culture media were analyzed using an antibody against the TrkB-FL extracellular domain (panTrkB), which recognizes the ectodomains (ECDs) of all isoforms (TrkB-ECD), to assess receptor shedding by metalloproteinase (MP) activation. Total lysates were analyzed with the TrkB-FL Ct antibody to evaluate TrkB-FL calpain processing via f32 production. Relative TrkB-ECD levels are shown as means ± SD (0-4 h, n = 7; 6 h, n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test (** P < 0.01, **** P < 0.0001, comparing each peptide + NMDA vs. peptide alone; # P < 0.05, #### P < 0.0001, comparing MTMyc vs. MTFL 457 at each time point). J , K Effect of NMDA on total and cell-surface pY816-TrkB-FL levels. Cultures were preincubated with peptides as above, then treated briefly with NMDA (1 h) to minimize receptor degradation. Cell-surface proteins were biotin-labeled and precipitated, then compared to corresponding total lysates. Data are represented as means ± SD ( n = 4). Statistical analysis: two-way ANOVA followed by Bonferroni post hoc test ( n.s . = n ot significant; ** P < 0.01, comparing NMDA vs. no NMDA; ## P < 0.01, comparing MTMyc + NMDA vs. MTFL 457 + NMDA).

Article Snippet: Primary antibodies against the following proteins were used: Hrs (Santa Cruz Biotechnology; Cat#sc-271455, RRID:AB_10648901), NSE (Millipore; Cat#AB951, RRID:AB_92390), spectrin alpha chain (Millipore; Cat#MAB1622, RRID:AB_94295), TrkB-FL C-ter (Santa Cruz Biotechnology; sc-11, RRID:AB_632554), TrkB extracellular sequences or panTrkB (Santa Cruz Biotechnology; sc-136990, RRID:AB_2155262), PSD-95 C-ter (Transduction Laboratories; Cat#610496, RRID:AB_2315218), pY816-TrkB-FL (Boster; Cat# P01388 ).

Techniques: Immunofluorescence, Western Blot, Staining, Activation Assay, Control, Labeling

A: BDNF band at approximately 27 kDa. B: GDNF band at approximately 20 kDa.

Journal: PLoS ONE

Article Title: S100B Protein, Brain-Derived Neurotrophic Factor, and Glial Cell Line-Derived Neurotrophic Factor in Human Milk

doi: 10.1371/journal.pone.0021663

Figure Lengend Snippet: A: BDNF band at approximately 27 kDa. B: GDNF band at approximately 20 kDa.

Article Snippet: Immunoblotting was performed using rabbit BDNF and GDNF antibodies (Wuhan Boster Bioligical Technology.,LTD, China).

Techniques:

M = DL500 DNA Marker. A: bands of β-actin at 256 bp. B: bands of S100B at 147 bp. C: bands of BDNF at 379 bp. D: bands of GDNF at 132 bp. The bands of cytokines from milks collected at day 3, 10, 30, 90 after parturition were not found to vary with time.

Journal: PLoS ONE

Article Title: S100B Protein, Brain-Derived Neurotrophic Factor, and Glial Cell Line-Derived Neurotrophic Factor in Human Milk

doi: 10.1371/journal.pone.0021663

Figure Lengend Snippet: M = DL500 DNA Marker. A: bands of β-actin at 256 bp. B: bands of S100B at 147 bp. C: bands of BDNF at 379 bp. D: bands of GDNF at 132 bp. The bands of cytokines from milks collected at day 3, 10, 30, 90 after parturition were not found to vary with time.

Article Snippet: Immunoblotting was performed using rabbit BDNF and GDNF antibodies (Wuhan Boster Bioligical Technology.,LTD, China).

Techniques: Marker